Souhaitez-vous accéder aux communiqués récents ?

NEWARK, Calif., May 26, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) ("Depomed" or the "Company") today issued the following statement in response to Starboard Value LP’s (“Starboard”)...

NEWARK, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that clinical data from Phase IIb trials of cebranopadol in chronic lower back pain (cLBP) and diabetic...

NEWARK, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that on May 18, 2016, Judge Claire C. Cecchi of the United States District Court for the District...

NEWARK, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that clinical data from two Phase IIb trials as well as human abuse potential and respiratory depression...

- First Quarter Revenues of $105M, up 225% over 1Q 2015 -- NUCYNTA® Franchise First Quarter 2016 Net Sales of $69 million, up 53% over 1Q 2015 -- Early Payment of $100M of Secured Debt Facility...

NEWARK, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the following healthcare conferences during the month of May. Bank...

NEWARK, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2016 financial results after the close of market,...

NEWARK, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) ("Depomed" or the "Company") today announced that it has established the close of business on April 26, 2016 as the...

      - Company Prepays Maximum Amount Allowed Under Agreement -      - Furthers Commitment to De-Levering the Company - NEWARK, Calif.,...

NEWARK, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- Depomed (NASDAQ:DEPO) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed the decisions of the Patent Trial and...